Nuvalent, Inc.
NUVLDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001861560
Nuvalent, Inc. was delisted in 2026; its insiders filed their last Form 4 on Jul 17, 2026; 292 institutions reported holding it in 13F filings for Q2 2026, worth $9.29B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 5
- Last 90 days, $8.91M in total
- 13F holders
- 292
- Q2 2026, +29 vs. previous quarter
- 13F value
- $9.29B
- Reported value at the end of Q2 2026
- Superinvestors holding
- 1
- At the end of Q2 2026
Superinvestors holding NUVL, Q2 2026
1 superinvestor reports holding Nuvalent, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
0.5%
Nuvalent, Inc.'s share of the portfolio
- Shares
- 300,017
- Value
- $37.1M
Latest insider trades
Open-market purchases and sales by Nuvalent, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 10, 2026 (view filing)4:30 PM ET | Jul 9 | 1 day | Pelish Henry E.Chief Scientific Officer | SSaleClass A Common Stock | −2.11K | $123.81 | −$261.4K | −3.2%63.5K after | 10b5-1 |
| Jul 8, 2026 (view filing)4:30 PM ET | Jul 6 | 2 days | Porter James RichardPresident and CEO | SSaleClass A Common Stock | −30.0K | $123.72 | −$3.71M | −8.5%324.9K after | 10b5-1 |
| Jul 6, 2026 (view filing)4:31 PM ET | Jul 1 | 5 days | Noci DarleneChief Development Officer | SSaleClass A Common Stock | −23.0K | $123.59 | −$2.84M | −28.4%58.1K after | 10b5-1 |
| Jul 6, 2026 (view filing)4:30 PM ET | Jul 1 | 5 days | Balcom AlexandraChief Financial Officer | SSaleClass A Common Stock | −11.4K | $123.58 | −$1.41M | −11.8%85.5K after | 10b5-1 |
| Jul 1, 2026 (view filing)4:30 PM ET | Jun 29 | 2 days | Noci DarleneChief Development Officer | SSaleClass A Common Stock | −5.50K | $123.51 | −$679.3K | −8.6%58.1K after | 10b5-1 |
| Jun 11, 2026 (view filing) | Jun 9 | 2 days | Noci DarleneChief Development Officer | SSaleClass A Common Stock | −20.0K | $122.81 | −$2.46M | −25.6%58.1K after | 10b5-1 |
| Jun 10, 2026 (view filing) | Jun 8 | 2 days | Porter James RichardPresident and CEO | SSaleClass A Common Stock | −30.0K | $88.53 | −$2.66M | −8.5%324.9K after | 3 lots10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Balcom AlexandraChief Financial Officer | SSaleClass A Common Stock | −11.4K | $98.69 | −$1.13M | −11.8%85.5K after | 8 lots10b5-1 |
| Jun 1, 2026 (view filing) | May 28 | 4 days | Miller Deborah AnnChief Legal Officer | SSaleClass A Common Stock | −5.50K | $107.84 | −$593.1K | −8.4%59.6K after | 4 lots10b5-1 |
| Jun 1, 2026 (view filing) | May 28 | 4 days | Noci DarleneChief Development Officer | SSaleClass A Common Stock | −5.50K | $107.80 | −$592.9K | −8.6%58.1K after | 5 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Nuvalent, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 17,248,450 | $2.13B | 22.22% | 00.0% | Unchanged |
| Paradigm Biocapital Advisors LP | 5,924,433 | $731.7M | 13.70% | +600,000+11.3% | Added |
| BlackRock, Inc. | 5,585,619 | $689.8M | 0.01% | +760,834+15.8% | Added |
| HBK Investments L P | 3,483,100 | $430.2M | 5.00% | +3,483,100 | New |
| FIL Ltd | 2,946,506 | $363.9M | 0.26% | +2,946,441+4,532,986.2% | Added |
| Vanguard Portfolio Management LLC | 2,589,282 | $319.8M | 0.01% | +88,375+3.5% | Added |
| Vanguard Capital Management LLC | 2,459,118 | $303.7M | 0.01% | +30,630+1.3% | Added |
| State Street Corp | 2,091,044 | $258.2M | 0.01% | +55,213+2.7% | Added |
| Deep Track Capital, LP | 1,783,322 | $220.2M | 3.24% | +406,998+29.6% | Added |
| Glazer Capital, LLC | 1,769,665 | $218.6M | 5.39% | +1,769,665 | New |